Department of Microbiology, Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela, India.
Indian J Pharmacol. 2011 Apr;43(2):113-20. doi: 10.4103/0253-7613.77335.
Presence of vitamin D receptors in noncalcemic tissues and subsequent identification of its involvement in growth factor(s)-mediated cellular function suggested its probable beneficial role in genesis, progression and survival of cancerous growths. Data collected from both in vitro and in vivo studies are highly optimistic regarding its potential in prevention and regression of colorectal, prostate and breast cancers. The vitamin has been found to interfere with the transduction pathways of various growth factor(s)-activated receptors (receptor tyrosine kinases) thereby modulating transcription and alteration of genomic functions resulting in inhibition of cell proliferation and angiogenesis and facilitation of cell differentiation and apoptosis. It also increases the level of an endogenous protein - cystatin D, which possesses antitumor and antimetastatic property, by facilitation of the expression of the gene coding for it. Though not as a primary anticancer agent, this vitamin may be used for the prevention of cancer and included as an adjuvant in combination chemotherapy for the treatment of cancer.
维生素 D 受体存在于非钙调组织中,随后其在生长因子(s)介导的细胞功能中的参与被确定,这表明其在癌性生长的发生、进展和存活中可能具有有益作用。来自体外和体内研究的数据对其在预防和消退结直肠癌、前列腺癌和乳腺癌方面的潜力非常乐观。已经发现这种维生素会干扰各种生长因子(受体酪氨酸激酶)激活的受体的转导途径,从而调节转录和基因组功能的改变,导致细胞增殖和血管生成的抑制以及细胞分化和凋亡的促进。它还通过促进编码它的基因的表达来增加内源性蛋白质 - 半胱氨酸蛋白酶抑制剂 D 的水平,该蛋白具有抗肿瘤和抗转移特性。虽然不是主要的抗癌药物,但这种维生素可用于预防癌症,并作为联合化疗的辅助剂用于癌症治疗。